caspofungin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antifungal antibiotics 2977 162808-62-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • caspofungin acetate
  • caspofungin diacetate
  • cancidas
  • caspofungin
  • MK-0991
Caspofungin, an echinocandin, inhibits the synthesis of beta (1,3)-D-glucan, an essential component of the cell wall of susceptible Aspergillus species and Candida species. Beta (1,3)-D-glucan is not present in mammalian cells. Caspofungin has shown activity against Candida species and in regions of active cell growth of the hyphae of Aspergillus fumigatus.
  • Molecular weight: 1093.33
  • Formula: C52H88N10O15
  • CLOGP: -2.35
  • LIPINSKI: 3
  • HAC: 25
  • HDO: 16
  • TPSA: 412.03
  • ALOGS: -3.47
  • ROTB: 23
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
50 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1.40 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.91 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 0.13 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.14 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.04 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 27 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 15 mg/mL Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,CAMK2D,CDK5,EIF2AK3,GRK2,ITK,NTRK2,PDK1,PDK2,PDK4,PRKDC 11
kinase-selectivity-class AXL,MAP2K6 2
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Jan. 26, 2001 FDA MERCK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple organ dysfunction syndrome 297.22 32.54 153 11232 68183 90548879
Drug ineffective 271.92 32.54 557 10828 1383741 89233321
Systemic mycosis 256.43 32.54 55 11330 1475 90615587
Septic shock 251.33 32.54 147 11238 84013 90533049
Systemic candida 210.27 32.54 59 11326 4900 90612162
Bronchopulmonary aspergillosis 188.44 32.54 66 11319 11332 90605730
Mucormycosis 187.55 32.54 51 11334 3770 90613292
Drug resistance 185.82 32.54 86 11299 30363 90586699
Febrile neutropenia 179.81 32.54 153 11232 158196 90458866
Aspergillus infection 168.74 32.54 60 11325 10763 90606299
Upper respiratory fungal infection 160.07 32.54 27 11358 184 90616878
Toxic epidermal necrolysis 150.47 32.54 76 11309 32452 90584610
Cholestasis 145.43 32.54 77 11308 36222 90580840
Pathogen resistance 134.17 32.54 47 11338 8068 90608994
Drug reaction with eosinophilia and systemic symptoms 133.63 32.54 77 11308 42681 90574381
Candida infection 124.54 32.54 68 11317 33989 90583073
Neutropenia 121.01 32.54 145 11240 224759 90392303
Respiratory failure 113.47 32.54 104 11281 118314 90498748
Graft versus host disease in gastrointestinal tract 102.64 32.54 33 11352 4355 90612707
Diffuse large B-cell lymphoma refractory 102.39 32.54 27 11358 1773 90615289
Fusarium infection 100.33 32.54 24 11361 1058 90616004
Venoocclusive liver disease 100.18 32.54 35 11350 5958 90611104
Hepatic cytolysis 97.44 32.54 56 11329 30860 90586202
Protothecosis 96.54 32.54 20 11365 451 90616611
Sepsis 95.13 32.54 115 11270 179699 90437363
Haemophagocytic lymphohistiocytosis 92.21 32.54 43 11342 15416 90601646
Bacteraemia 91.26 32.54 48 11337 22252 90594810
Thrombocytopenia 90.66 32.54 121 11264 208604 90408458
Candida sepsis 90.23 32.54 24 11361 1629 90615433
Disseminated mucormycosis 89.49 32.54 20 11365 651 90616411
Fungal infection 88.01 32.54 59 11326 42602 90574460
Cerebral aspergillosis 86.96 32.54 19 11366 556 90616506
Enterococcal infection 86.14 32.54 36 11349 9955 90607107
Toxic skin eruption 85.27 32.54 41 11344 15733 90601329
Acute respiratory distress syndrome 82.58 32.54 49 11336 28637 90588425
Fungal sepsis 82.34 32.54 22 11363 1519 90615543
Graft versus host disease 79.24 32.54 32 11353 8112 90608950
Fungaemia 77.56 32.54 25 11360 3325 90613737
Alternaria infection 77.26 32.54 16 11369 360 90616702
Geotrichum infection 74.76 32.54 17 11368 599 90616463
Acute kidney injury 73.96 32.54 139 11246 320248 90296814
Pyelonephritis fungal 73.48 32.54 14 11371 202 90616860
Cytomegalovirus infection 72.83 32.54 44 11341 26558 90590504
Disseminated intravascular coagulation 70.51 32.54 40 11345 21498 90595564
Fatigue 69.90 32.54 29 11356 1153994 89463068
Perinephric abscess 68.25 32.54 14 11371 300 90616762
Emphysematous pyelonephritis 66.42 32.54 14 11371 344 90616718
Stevens-Johnson syndrome 66.34 32.54 43 11342 29333 90587729
Graft versus host disease in skin 66.31 32.54 23 11362 3830 90613232
Hepatic failure 65.73 32.54 48 11337 39680 90577382
Hyperbilirubinaemia 65.70 32.54 33 11352 13903 90603159
Product use in unapproved indication 64.48 32.54 135 11250 336101 90280961
Escherichia bacteraemia 64.42 32.54 25 11360 5710 90611352
Adenoviral hepatitis 63.17 32.54 14 11371 438 90616624
Dysbiosis 62.02 32.54 18 11367 1684 90615378
Hepatocellular injury 59.60 32.54 40 11345 28918 90588144
Graft versus host disease in liver 57.43 32.54 15 11370 948 90616114
Brain oedema 56.13 32.54 32 11353 17353 90599709
Dizziness 55.76 32.54 5 11380 589279 90027783
Acute graft versus host disease 54.97 32.54 22 11363 5446 90611616
Renal failure 53.85 32.54 74 11311 130933 90486129
Cytokine release syndrome 53.67 32.54 37 11348 27936 90589126
Headache 53.26 32.54 21 11364 862725 89754337
Pain 52.71 32.54 30 11355 996311 89620751
Systemic inflammatory response syndrome 51.25 32.54 22 11363 6494 90610568
Vesicoureteric reflux 51.19 32.54 11 11374 297 90616765
Staphylococcal bacteraemia 48.36 32.54 22 11363 7447 90609615
Pancytopenia 48.02 32.54 67 11318 120196 90496866
Arthralgia 47.94 32.54 19 11366 778503 89838559
Coagulation test abnormal 47.82 32.54 13 11372 958 90616104
Infective aneurysm 47.34 32.54 11 11374 427 90616635
Eosinophilia 46.12 32.54 34 11351 28499 90588563
Abdominal discomfort 45.27 32.54 4 11381 477324 90139738
Fungal test positive 44.71 32.54 11 11374 546 90616516
Adenovirus infection 44.41 32.54 18 11367 4604 90612458
Pyrexia 44.37 32.54 182 11203 660303 89956759
Agranulocytosis 44.13 32.54 36 11349 34966 90582096
Hepatotoxicity 43.34 32.54 40 11345 45802 90571260
Rash maculo-papular 43.19 32.54 38 11347 40895 90576167
Drug level decreased 42.83 32.54 22 11363 9708 90607354
Bacterial infection 42.61 32.54 30 11355 23414 90593648
Capillary leak syndrome 41.83 32.54 15 11370 2752 90614310
Hepatic necrosis 41.80 32.54 19 11366 6419 90610643
Dyspnoea 41.80 32.54 30 11355 880925 89736137
Nausea 41.74 32.54 47 11338 1110269 89506793
Paraspinal abscess 41.10 32.54 9 11376 266 90616796
Rhinocerebral mucormycosis 40.59 32.54 11 11374 801 90616261
Coagulopathy 40.48 32.54 29 11356 23260 90593802
Overgrowth fungal 40.17 32.54 8 11377 147 90616915
Renal impairment 39.52 32.54 57 11328 105364 90511698
Swelling 38.44 32.54 4 11381 419054 90198008
Cerebral haemorrhage 38.34 32.54 33 11352 34489 90582573
Trichosporon infection 38.18 32.54 9 11376 372 90616690
Peripheral swelling 37.75 32.54 4 11381 413102 90203960
Peritonitis 37.64 32.54 26 11359 19679 90597383
Mucosal inflammation 37.39 32.54 41 11344 57584 90559478
Urinary tract candidiasis 36.72 32.54 10 11375 742 90616320
Pseudomonas infection 36.64 32.54 23 11362 14842 90602220
Dilatation intrahepatic duct acquired 36.51 32.54 10 11375 758 90616304
Abscess 36.26 32.54 25 11360 18866 90598196
Renal tubular disorder 36.09 32.54 14 11371 3193 90613869
Drug level increased 35.94 32.54 29 11356 27733 90589329
Infusion related reaction 35.71 32.54 5 11380 416775 90200287
Multiple-drug resistance 35.44 32.54 18 11367 7758 90609304
Cytomegalovirus infection reactivation 35.39 32.54 18 11367 7782 90609280
Liver abscess 34.91 32.54 14 11371 3482 90613580
Venous haemorrhage 34.62 32.54 8 11377 303 90616759
Drug level below therapeutic 34.13 32.54 16 11369 5798 90611264
Staphylococcal scalded skin syndrome 34.08 32.54 7 11378 151 90616911
Cytomegalovirus gastritis 33.81 32.54 8 11377 336 90616726
Polyserositis 33.10 32.54 9 11376 664 90616398
Myelosuppression 32.82 32.54 37 11348 53554 90563508
Liver function test abnormal 32.68 32.54 36 11349 50809 90566253
Epidermolysis 32.63 32.54 9 11376 700 90616362
Abscess fungal 32.59 32.54 6 11379 71 90616991

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 486.60 23.47 792 13294 629405 41977844
Multiple organ dysfunction syndrome 301.31 23.47 252 13834 96783 42510466
Drug resistance 249.63 23.47 150 13936 34098 42573151
Aspergillus infection 245.99 23.47 115 13971 15722 42591527
Systemic mycosis 240.47 23.47 69 14017 2318 42604931
Bronchopulmonary aspergillosis 197.98 23.47 106 13980 19323 42587926
Septic shock 179.06 23.47 184 13902 91488 42515761
Pathogen resistance 162 23.47 78 14008 11372 42595877
Solar lentigo 149.53 23.47 36 14050 598 42606651
Dysplastic naevus 146.60 23.47 36 14050 652 42606597
Photodermatosis 143.04 23.47 36 14050 724 42606525
Candida infection 135.36 23.47 86 14000 21524 42585725
Mucormycosis 133.37 23.47 59 14027 7084 42600165
Drug reaction with eosinophilia and systemic symptoms 123.51 23.47 106 13980 41969 42565280
Central nervous system fungal infection 118.65 23.47 28 14058 425 42606824
Fungal infection 112.46 23.47 74 14012 19648 42587601
Fungaemia 107.22 23.47 40 14046 3096 42604153
Systemic candida 106.00 23.47 46 14040 5273 42601976
Agranulocytosis 95.72 23.47 80 14006 30532 42576717
Cholestasis 77.05 23.47 73 14013 32806 42574443
Fatigue 75.71 23.47 25 14061 435616 42171633
Actinic keratosis 75.43 23.47 36 14050 5140 42602109
Respiratory failure 74.96 23.47 144 13942 127988 42479261
Enterococcal infection 70.63 23.47 46 14040 11993 42595256
Pulmonary mucormycosis 70.35 23.47 24 14062 1431 42605818
Febrile neutropenia 68.10 23.47 173 13913 185530 42421719
Trichosporon infection 67.55 23.47 21 14065 931 42606318
Sepsis 65.26 23.47 178 13908 199156 42408093
Scedosporium infection 64.92 23.47 23 14063 1535 42605714
Fusarium infection 60.35 23.47 22 14064 1594 42605655
Product use in unapproved indication 58.65 23.47 163 13923 184293 42422956
Cytomegalovirus infection 57.83 23.47 62 14024 32244 42575005
Haemophagocytic lymphohistiocytosis 57.72 23.47 48 14038 18174 42589075
Nephrogenic diabetes insipidus 57.20 23.47 21 14065 1553 42605696
Photosensitivity reaction 56.68 23.47 41 14045 12661 42594588
Venoocclusive disease 56.35 23.47 27 14059 3888 42603361
Fall 56.34 23.47 6 14080 234514 42372735
Dizziness 55.92 23.47 8 14078 249246 42358003
Toxic epidermal necrolysis 54.46 23.47 55 14031 26695 42580554
Dyspnoea 53.53 23.47 41 14045 442580 42164669
Pseudomonas infection 52.64 23.47 43 14043 15880 42591369
Hypokalaemia 52.60 23.47 89 13997 71632 42535617
Stenotrophomonas infection 48.66 23.47 24 14062 3680 42603569
Cerebral aspergillosis 47.66 23.47 19 14067 1758 42605491
Arthralgia 47.41 23.47 6 14080 205232 42402017
Differentiation syndrome 47.29 23.47 19 14067 1794 42605455
Splenic infection fungal 46.12 23.47 10 14076 101 42607148
Weight decreased 45.87 23.47 7 14079 207941 42399308
Nausea 45.15 23.47 39 14047 396760 42210489
Pancytopenia 44.45 23.47 111 13975 117632 42489617
Aortoenteric fistula 44.32 23.47 10 14076 123 42607126
Pain 44.31 23.47 13 14073 244835 42362414
Asthenia 43.86 23.47 19 14067 280774 42326475
Squamous cell carcinoma of skin 43.40 23.47 35 14051 12691 42594558
Toxic skin eruption 43.13 23.47 36 14050 13694 42593555
Hyperbilirubinaemia 43.05 23.47 43 14043 20592 42586657
Incision site pain 43.01 23.47 18 14068 1885 42605364
Endocarditis 42.63 23.47 29 14057 8123 42599126
Geotrichum infection 42.08 23.47 13 14073 564 42606685
Hepatic failure 41.73 23.47 57 14029 38043 42569206
Off label use 40.94 23.47 354 13732 637981 41969268
Haemodynamic instability 39.60 23.47 33 14053 12524 42594725
Decreased appetite 37.31 23.47 9 14077 193128 42414121
Graft versus host disease 36.74 23.47 32 14054 12893 42594356
Encephalopathy 36.73 23.47 56 14030 41277 42565972
Splenic abscess 36.35 23.47 12 14074 646 42606603
Vomiting 36.03 23.47 26 14060 289697 42317552
Acute respiratory distress syndrome 35.97 23.47 47 14039 30061 42577188
Graft versus host disease in skin 35.78 23.47 22 14064 5190 42602059
Bone marrow failure 35.47 23.47 49 14037 33044 42574205
Hyperleukocytosis 34.56 23.47 17 14069 2591 42604658
Acute generalised exanthematous pustulosis 34.43 23.47 26 14060 8569 42598680
Lymphocyte count decreased 34.14 23.47 44 14042 27765 42579484
Malaise 33.67 23.47 14 14072 212142 42395107
Drug ineffective for unapproved indication 33.45 23.47 57 14029 46106 42561143
Lower respiratory tract infection fungal 33.25 23.47 11 14075 596 42606653
Organ failure 32.62 23.47 16 14070 2424 42604825
Scopulariopsis infection 32.11 23.47 8 14078 154 42607095
Fungal abscess central nervous system 31.77 23.47 8 14078 161 42607088
Graft versus host disease in gastrointestinal tract 31.02 23.47 20 14066 5123 42602126
Rectal perforation 30.23 23.47 10 14076 542 42606707
Red blood cells urine positive 30.03 23.47 14 14072 1896 42605353
Transaminases increased 29.85 23.47 45 14041 32840 42574409
Microangiopathic haemolytic anaemia 29.84 23.47 12 14074 1135 42606114
Renal tubular disorder 29.38 23.47 19 14067 4890 42602359
Liver abscess 29.17 23.47 19 14067 4951 42602298
Hepatotoxicity 28.08 23.47 38 14048 25129 42582120
Aspergilloma 27.98 23.47 9 14077 446 42606803
Pneumonia bacterial 27.87 23.47 30 14056 15662 42591587
Gastrointestinal fungal infection 27.86 23.47 8 14078 269 42606980
Headache 27.81 23.47 23 14063 239346 42367903
Fungal endocarditis 27.81 23.47 9 14077 455 42606794
Electrocardiogram QT prolonged 26.89 23.47 53 14033 47892 42559357
Arteritis infective 26.80 23.47 6 14080 71 42607178
Systemic inflammatory response syndrome 26.64 23.47 21 14065 7369 42599880
Protein urine present 26.51 23.47 19 14067 5782 42601467
Depression 26.32 23.47 3 14083 111360 42495889
Pruritus 26.09 23.47 15 14071 188756 42418493
Renal failure 25.91 23.47 105 13981 143621 42463628
Pain in extremity 25.44 23.47 9 14077 150595 42456654
Intestinal haemorrhage 25.41 23.47 16 14070 3935 42603314
Hepatic function abnormal 25.37 23.47 54 14032 51513 42555736
Weight increased 25.30 23.47 3 14083 107980 42499269
Spinal cord disorder 24.83 23.47 10 14076 950 42606299
Enamel anomaly 24.41 23.47 7 14079 234 42607015
Thoracic haemorrhage 24.41 23.47 7 14079 234 42607015
Disseminated mucormycosis 24.39 23.47 11 14075 1380 42605869
Hypoperfusion 24.28 23.47 11 14075 1394 42605855
Hypogonadism 23.98 23.47 13 14073 2421 42604828
Chimerism 23.94 23.47 7 14079 251 42606998
Anxiety 23.93 23.47 5 14081 118555 42488694
Clostridium difficile colitis 23.57 23.47 32 14054 21220 42586029
Mucosal inflammation 23.48 23.47 51 14035 49323 42557926

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 802.25 25.96 1295 23272 1519245 109045487
Multiple organ dysfunction syndrome 569.46 25.96 377 24190 151333 110413399
Systemic mycosis 489.96 25.96 123 24444 3706 110561026
Aspergillus infection 406.94 25.96 168 24399 25448 110539284
Bronchopulmonary aspergillosis 395.10 25.96 172 24395 29691 110535041
Septic shock 376.70 25.96 298 24269 157230 110407502
Systemic candida 298.71 25.96 104 24463 9870 110554862
Drug resistance 291.67 25.96 172 24395 56202 110508530
Mucormycosis 280.92 25.96 101 24466 10527 110554205
Pathogen resistance 277.58 25.96 115 24452 17557 110547175
Candida infection 252.33 25.96 148 24419 47861 110516871
Drug reaction with eosinophilia and systemic symptoms 241.74 25.96 176 24391 81919 110482813
Febrile neutropenia 216.76 25.96 307 24260 316460 110248272
Cholestasis 193.73 25.96 140 24427 64378 110500354
Toxic epidermal necrolysis 186.26 25.96 130 24437 56597 110508135
Respiratory failure 182.85 25.96 232 24335 215100 110349632
Fungal infection 158.83 25.96 113 24454 50693 110514039
Dysplastic naevus 153.32 25.96 36 24531 812 110563920
Enterococcal infection 151.58 25.96 79 24488 20287 110544445
Fungaemia 150.23 25.96 55 24512 6031 110558701
Haemophagocytic lymphohistiocytosis 149.43 25.96 91 24476 31468 110533264
Upper respiratory fungal infection 148.59 25.96 31 24536 396 110564336
Sepsis 144.70 25.96 260 24307 327086 110237646
Photodermatosis 144.30 25.96 36 24531 1055 110563677
Fatigue 141.95 25.96 47 24520 1215911 109348821
Agranulocytosis 132.89 25.96 110 24457 61650 110503082
Solar lentigo 132.36 25.96 36 24531 1488 110563244
Fusarium infection 127.61 25.96 40 24527 2731 110562001
Cytomegalovirus infection 125.62 25.96 101 24466 54343 110510389
Central nervous system fungal infection 115.62 25.96 27 24540 594 110564138
Toxic skin eruption 111.78 25.96 72 24495 27443 110537289
Geotrichum infection 111.69 25.96 30 24537 1182 110563550
Dizziness 110.29 25.96 13 24554 698180 109866552
Product use in unapproved indication 108.00 25.96 278 24289 447099 110117633
Graft versus host disease 106.79 25.96 61 24506 18745 110545987
Trichosporon infection 104.98 25.96 29 24538 1271 110563461
Acute respiratory distress syndrome 104.66 25.96 90 24477 53108 110511624
Pain 104.35 25.96 41 24526 954914 109609818
Hepatic failure 103.34 25.96 100 24467 68639 110496093
Hyperbilirubinaemia 102.31 25.96 71 24496 30600 110534132
Arthralgia 102.22 25.96 24 24543 779608 109785124
Pancytopenia 100.95 25.96 173 24394 209440 110355292
Disseminated mucormycosis 99.55 25.96 31 24536 2071 110562661
Venoocclusive liver disease 99.10 25.96 54 24513 15153 110549579
Dyspnoea 95.08 25.96 65 24502 1106807 109457925
Scedosporium infection 94.78 25.96 31 24536 2427 110562305
Headache 94.55 25.96 39 24528 882338 109682394
Acute kidney injury 92.13 25.96 330 24237 635100 109929632
Protothecosis 92.11 25.96 22 24545 535 110564197
Neutropenia 90.56 25.96 233 24334 374387 110190345
Pseudomonas infection 87.14 25.96 62 24505 27791 110536941
Nausea 87.11 25.96 88 24479 1235602 109329130
Graft versus host disease in gastrointestinal tract 85.02 25.96 41 24526 8927 110555805
Fall 82.24 25.96 17 24550 603465 109961267
Bacteraemia 81.93 25.96 71 24496 42319 110522413
Disseminated intravascular coagulation 81.51 25.96 70 24497 41216 110523516
Cerebral aspergillosis 80.62 25.96 27 24540 2275 110562457
Venoocclusive disease 78.83 25.96 35 24532 6315 110558417
Actinic keratosis 78.63 25.96 36 24531 6977 110557755
Pulmonary mucormycosis 78.50 25.96 26 24541 2117 110562615
Candida sepsis 77.70 25.96 28 24539 2933 110561799
Peripheral swelling 76.71 25.96 3 24564 404031 110160701
Systemic inflammatory response syndrome 75.92 25.96 43 24524 13000 110551732
Renal failure 74.46 25.96 159 24408 226415 110338317
Stenotrophomonas infection 71.80 25.96 32 24535 5826 110558906
Abdominal discomfort 71.30 25.96 4 24563 393854 110170878
Off label use 70.35 25.96 570 23997 1499615 109065117
Bone marrow failure 70.24 25.96 75 24492 57773 110506959
Alopecia 68.26 25.96 3 24564 364750 110199982
Encephalopathy 68.15 25.96 87 24480 80968 110483764
Cytokine release syndrome 68.03 25.96 81 24486 70225 110494507
Graft versus host disease in skin 67.14 25.96 34 24533 8220 110556512
Weight decreased 66.24 25.96 12 24555 468045 110096687
Alternaria infection 65.53 25.96 19 24548 993 110563739
Organ failure 64.49 25.96 28 24539 4789 110559943
Asthenia 63.80 25.96 37 24530 688962 109875770
Hypokalaemia 63.38 25.96 131 24436 182317 110382415
Eosinophilia 63.19 25.96 71 24496 57865 110506867
Acute graft versus host disease 63.16 25.96 38 24529 12843 110551889
Hepatotoxicity 62.93 25.96 74 24493 63326 110501406
Infusion related reaction 62.92 25.96 6 24561 381156 110183576
Swelling 62.21 25.96 4 24563 351037 110213695
Fungal sepsis 61.89 25.96 22 24545 2215 110562517
Renal tubular disorder 61.59 25.96 31 24536 7398 110557334
Hepatocellular injury 60.32 25.96 65 24502 50577 110514155
Hepatic function abnormal 60.07 25.96 86 24481 89209 110475523
Nephrogenic diabetes insipidus 59.98 25.96 22 24545 2423 110562309
Pyelonephritis fungal 59.78 25.96 14 24553 312 110564420
Drug ineffective for unapproved indication 59.10 25.96 92 24475 102746 110461986
Rash maculo-papular 58.23 25.96 77 24490 74145 110490587
Hepatic cytolysis 57.55 25.96 66 24501 54987 110509745
Vomiting 57.31 25.96 71 24496 910604 109654128
Stevens-Johnson syndrome 57.27 25.96 61 24506 46840 110517892
Weight increased 56.76 25.96 12 24555 419632 110145100
Drug intolerance 56.28 25.96 11 24556 406501 110158231
Perinephric abscess 56.02 25.96 14 24553 413 110564319
Drug hypersensitivity 55.56 25.96 16 24551 454074 110110658
Differentiation syndrome 55.30 25.96 22 24545 3022 110561710
Incision site pain 54.67 25.96 22 24545 3113 110561619
Bacterial infection 52.93 25.96 58 24509 45978 110518754
Pruritus 52.73 25.96 32 24535 581528 109983204
Decreased appetite 52.56 25.96 20 24547 475826 110088906
Emphysematous pyelonephritis 51.82 25.96 14 24553 564 110564168
Dysbiosis 51.63 25.96 19 24548 2113 110562619
Myelosuppression 50.90 25.96 82 24485 94258 110470474
Fungal test positive 50.78 25.96 16 24551 1111 110563621
Lymphocyte count decreased 50.58 25.96 63 24504 57180 110507552
Malaise 50.51 25.96 45 24522 671774 109892958
Drug interaction 50.21 25.96 232 24335 499951 110064781
Electrocardiogram QT prolonged 49.88 25.96 88 24479 108872 110455860
Depression 49.80 25.96 6 24561 317329 110247403
Photosensitivity reaction 49.72 25.96 43 24524 25546 110539186
Endocarditis 49.45 25.96 33 24534 13338 110551394
Vesicoureteric reflux 49.09 25.96 11 24556 200 110564532
Graft versus host disease in liver 48.94 25.96 19 24548 2446 110562286
Splenic abscess 48.41 25.96 15 24552 985 110563747
Pain in extremity 48.21 25.96 24 24543 487094 110077638
Klebsiella infection 48.01 25.96 38 24529 19971 110544761
Staphylococcal bacteraemia 47.31 25.96 35 24532 16653 110548079
Abdominal pain upper 47.16 25.96 10 24557 349101 110215631
Transaminases increased 47.03 25.96 64 24503 63326 110501406
Red blood cells urine positive 47.03 25.96 23 24544 5162 110559570
Gait disturbance 46.92 25.96 4 24563 278204 110286528
Aortoenteric fistula 46.50 25.96 10 24557 149 110564583
Anxiety 46.38 25.96 10 24557 345068 110219664
Squamous cell carcinoma of skin 46.36 25.96 35 24532 17168 110547564
Rhinocerebral mucormycosis 46.11 25.96 16 24551 1501 110563231
Drug level below therapeutic 46.06 25.96 30 24537 11643 110553089
Thrombocytopenia 46.05 25.96 176 24391 348709 110216023
Splenic infection fungal 45.89 25.96 10 24557 159 110564573
Insomnia 45.42 25.96 12 24555 360578 110204154
Abscess fungal 45.40 25.96 12 24555 444 110564288
Adenovirus infection 45.21 25.96 29 24538 10965 110553767
Escherichia bacteraemia 44.77 25.96 28 24539 10136 110554596
Pneumonia fungal 44.21 25.96 32 24535 14722 110550010
Adenoviral hepatitis 44.07 25.96 14 24553 998 110563734
Drug level decreased 44.02 25.96 35 24532 18513 110546219
Haemodynamic instability 43.54 25.96 38 24529 22850 110541882
Enterococcal sepsis 43.52 25.96 19 24548 3293 110561439
Gastrointestinal fungal infection 43.33 25.96 13 24554 766 110563966
Staphylococcal scalded skin syndrome 43.28 25.96 12 24555 533 110564199
Mucosal inflammation 43.17 25.96 77 24490 96064 110468668
Multiple-drug resistance 42.64 25.96 30 24537 13205 110551527
Infective aneurysm 42.52 25.96 15 24552 1477 110563255
Hypoaesthesia 42.44 25.96 9 24558 314214 110250518
Lower respiratory tract infection fungal 42.10 25.96 13 24554 844 110563888
Mobility decreased 41.19 25.96 3 24564 237419 110327313
Contraindicated product administered 40.71 25.96 4 24563 248263 110316469
Blood pressure increased 40.25 25.96 5 24562 258368 110306364
Chimerism 39.51 25.96 10 24557 311 110564421
Renal impairment 39.20 25.96 111 24456 188334 110376398
Pneumonia bacterial 39.06 25.96 38 24529 26223 110538509
Brain abscess 38.53 25.96 22 24545 6752 110557980
Liver abscess 38.38 25.96 23 24544 7716 110557016
BK virus infection 38.30 25.96 28 24539 13078 110551654
Cytomegalovirus infection reactivation 38.06 25.96 32 24535 18301 110546431
Urinary tract candidiasis 37.81 25.96 13 24554 1186 110563546
Coagulopathy 37.71 25.96 46 24521 40865 110523867
Nosocomial infection 37.69 25.96 17 24550 3182 110561550
Cerebral haemorrhage 37.15 25.96 58 24509 64910 110499822
Acute graft versus host disease in intestine 36.67 25.96 20 24547 5619 110559113
Hyperleukocytosis 36.51 25.96 17 24550 3422 110561310
Hepatitis fulminant 36.25 25.96 23 24544 8537 110556195
Acute generalised exanthematous pustulosis 35.36 25.96 33 24534 21631 110543101
Overgrowth fungal 35.32 25.96 8 24559 153 110564579
Sinusitis 35.28 25.96 11 24556 296677 110268055
Drug level increased 35.12 25.96 48 24519 47671 110517061
Protein urine present 34.62 25.96 25 24542 11459 110553273
Scopulariopsis infection 34.30 25.96 8 24559 175 110564557
Leukopenia 34.28 25.96 91 24476 148700 110416032
Coagulation test abnormal 34.26 25.96 13 24554 1573 110563159
Abscess 34.02 25.96 36 24531 27433 110537299
Hepatic necrosis 33.15 25.96 23 24544 9899 110554833
Hypoproteinaemia 32.99 25.96 19 24548 5926 110558806
Lower respiratory tract infection 32.75 25.96 7 24560 243099 110321633
Fungal abscess central nervous system 32.59 25.96 8 24559 219 110564513
Disseminated trichosporonosis 32.45 25.96 8 24559 223 110564509
Peritonitis 32.25 25.96 38 24529 32569 110532163
Nephropathy toxic 32.24 25.96 35 24532 27443 110537289
Bacterial sepsis 32.12 25.96 23 24544 10403 110554329
Paraspinal abscess 32.09 25.96 9 24558 417 110564315
Acute hepatic failure 32.00 25.96 40 24527 36428 110528304
Microangiopathic haemolytic anaemia 31.70 25.96 13 24554 1930 110562802
Hypersensitivity 31.62 25.96 26 24541 403972 110160760
Hyperhidrosis 30.75 25.96 3 24564 187295 110377437
Hypertension 30.74 25.96 41 24526 510043 110054689
Pulmonary haemorrhage 30.66 25.96 27 24540 16429 110548303
Platelet count decreased 30.17 25.96 116 24451 230327 110334405
Pericarditis 30.15 25.96 6 24561 219108 110345624
Fungal endocarditis 30.05 25.96 10 24557 826 110563906
Dilatation intrahepatic duct acquired 29.97 25.96 10 24557 833 110563899
Osteoarthritis 29.79 25.96 3 24564 182620 110382112
Septic embolus 29.45 25.96 13 24554 2313 110562419
Enterocolitis 29.28 25.96 28 24539 18921 110545811
Shock haemorrhagic 29.04 25.96 33 24534 27214 110537518
Dyspepsia 29.01 25.96 4 24563 190961 110373771
Injection site pain 28.82 25.96 3 24564 177919 110386813
Neutrophil count increased 28.81 25.96 37 24530 34615 110530117
Brain oedema 28.72 25.96 35 24532 31063 110533669
Venous haemorrhage 28.56 25.96 8 24559 369 110564363
Pyrexia 28.17 25.96 314 24253 897951 109666781
Rectal perforation 27.94 25.96 10 24557 1027 110563705
Cytomegalovirus gastritis 27.84 25.96 9 24558 679 110564053
Clostridium difficile colitis 27.74 25.96 41 24526 43737 110520995
Hepatic artery aneurysm 27.62 25.96 6 24561 94 110564638
Staphylococcal sepsis 27.36 25.96 26 24541 17428 110547304
Chronic graft versus host disease 27.18 25.96 20 24547 9437 110555295
Enamel anomaly 27.08 25.96 7 24560 237 110564495
Fungal skin infection 27.07 25.96 18 24549 7231 110557501
Immune effector cell-associated neurotoxicity syndrome 27.03 25.96 24 24543 14758 110549974
Blood bilirubin increased 26.88 25.96 55 24512 75917 110488815
Paraesthesia 26.77 25.96 14 24553 276507 110288225
Pneumothorax 26.74 25.96 36 24531 35249 110529483
Arthritis 26.70 25.96 3 24564 167583 110397149
Aspergilloma 26.51 25.96 9 24558 790 110563942
Acute myeloid leukaemia 26.05 25.96 37 24530 38073 110526659

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J02AX04 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOTICS FOR SYSTEMIC USE
ANTIMYCOTICS FOR SYSTEMIC USE
Other antimycotics for systemic use
FDA CS M0519359 Lipopeptides
FDA EPC N0000175507 Echinocandin Antifungal
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000935 Antifungal Agents
MeSH PA D004791 Enzyme Inhibitors
CHEBI has role CHEBI:35441 antiinfective agent

Related Drugs by ATC class:

J02AX Other antimycotics for systemic use 5 drugs
anidulafunginflucytosineibrexafungerpmicafunginrezafungin

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Candidiasis of the esophagus indication 20639004 DOID:13146
Candidemia indication 432261003
Intra-Abdominal Candida Abscess indication
Candida Pleural Space Infection indication
Refractory Aspergillosis indication
Candida Peritonitis indication
Oropharyngeal Candidiasis off-label use
Hypokalemia contraindication 43339004
Liver function tests abnormal contraindication 166603001
Disease of liver contraindication 235856003 DOID:409




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.55 acidic
pKa2 11.98 acidic
pKa3 13.1 acidic
pKa4 13.77 acidic
pKa5 13.84 acidic
pKa6 10.04 Basic
pKa7 9.05 Basic
pKa8 4.09 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
ATP-binding cassette sub-family G member 2 Transporter IC50 5.22 CHEMBL
Beta-1,3-glucan synthase catalytic subunit 1 Enzyme INHIBITOR IC50 8.89 WOMBAT-PK CHEMBL
1,3-beta-glucan synthase catalytic subunit FksP Enzyme INHIBITOR CHEMBL CHEMBL
1,3-beta-D-glucan synthase catalytic subunit Enzyme IC50 9.62 CHEMBL

External reference:

IDSource
4021254 VUID
N0000148695 NUI
D02501 KEGG_DRUG
179463-17-3 SECONDARY_CAS_RN
4021253 VANDF
4021254 VANDF
C0537894 UMLSCUI
CHEBI:474180 CHEBI
CHEMBL1630575 ChEMBL_ID
CHEMBL5314378 ChEMBL_ID
D000077336 MESH_DESCRIPTOR_UI
DB00520 DRUGBANK_ID
7778 INN_ID
F0XDI6ZL63 UNII
16119814 PUBCHEM_CID
140108 RXNORM
15896 MMSL
260563 MMSL
41099 MMSL
d04748 MMSL
009069 NDDF
009070 NDDF
129474002 SNOMEDCT_US
407732005 SNOMEDCT_US
413770001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
CANCIDAS HUMAN PRESCRIPTION DRUG LABEL 1 0006-3822 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS NDA 28 sections
CANCIDAS HUMAN PRESCRIPTION DRUG LABEL 1 0006-3822 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS NDA 28 sections
CANCIDAS HUMAN PRESCRIPTION DRUG LABEL 1 0006-3823 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 7 mg INTRAVENOUS NDA 28 sections
CANCIDAS HUMAN PRESCRIPTION DRUG LABEL 1 0006-3823 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 7 mg INTRAVENOUS NDA 28 sections
CASPOFUNGIN ACETATE HUMAN PRESCRIPTION DRUG LABEL 1 0781-3421 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 27 sections
CASPOFUNGIN ACETATE HUMAN PRESCRIPTION DRUG LABEL 1 0781-3423 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 7 mg INTRAVENOUS ANDA 27 sections
Caspofungin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 25021-194 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 31 sections
Caspofungin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 25021-195 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 7 mg INTRAVENOUS ANDA 31 sections
CASPOFUNGIN ACETATE HUMAN PRESCRIPTION DRUG LABEL 1 59923-613 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 7 mg INTRAVENOUS ANDA 28 sections
CASPOFUNGIN ACETATE HUMAN PRESCRIPTION DRUG LABEL 1 59923-614 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 28 sections
Caspofungin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 63323-356 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS NDA 29 sections
Caspofungin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 63323-358 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 7 mg INTRAVENOUS NDA 29 sections
CASPOFUNGIN ACETATE HUMAN PRESCRIPTION DRUG LABEL 1 65897-0002 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 18 sections
CASPOFUNGIN ACETATE HUMAN PRESCRIPTION DRUG LABEL 1 65897-0002 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 18 sections
CASPOFUNGIN ACETATE HUMAN PRESCRIPTION DRUG LABEL 1 65897-0003 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 7 mg INTRAVENOUS ANDA 18 sections
CASPOFUNGIN ACETATE HUMAN PRESCRIPTION DRUG LABEL 1 65897-0004 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 7 mg INTRAVENOUS ANDA 18 sections
Caspofungin Acetate Human Prescription Drug Label 1 68083-158 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 26 sections
Caspofungin Acetate Human Prescription Drug Label 1 68083-159 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 7 mg INTRAVENOUS ANDA 26 sections
Caspofungin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 72266-106 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 26 sections
Caspofungin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 72266-107 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 7 mg INTRAVENOUS ANDA 26 sections
caspofungin acetate HUMAN PRESCRIPTION DRUG LABEL 1 72611-700 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 28 sections
Caspofungin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 72611-702 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 7 mg INTRAVENOUS ANDA 28 sections